论文部分内容阅读
20世纪20年代,注射性胰岛素的问世给糖尿病患者带来生存的希望。但是每天多次的注射,使得患者的依从性降低,对血糖的控制不尽理想。多年来,研究者们一直致力于研究另一种的胰岛素给药途径的可能性,其中包括吸入式胰岛素。但是吸入式胰岛素临床研究的多次失败一度让这个希望几乎破灭。但是近年来,礼来、辉瑞、诺和诺德、赛诺菲-安万特等几家公司经过不懈的努力已经进入吸入式胰岛素的末期临床研究阶段,并取得了可喜的研究结果。其中,辉瑞公司的吸入式胰岛素——Exubera已于2006年1月被批准上市。据有关专家预测,吸入式胰岛素的上市将会对胰岛素市场造成不小的冲击。事实是否如此,我们拭目以待。
In the 1920s, the advent of injectable insulin brought hope for the survival of people with diabetes. However, multiple daily injections, making patients less compliance, blood sugar control less than ideal. Over the years, researchers have been working on the possibility of studying alternative insulin delivery routes, including inhaled insulin. However, many failures in the clinical study of inhaled insulin have almost dashed this hope. However, in recent years, several companies, including Eli Lilly, Pfizer, Novo Nordisk and Sanofi-Aventis have made unremitting efforts to enter the final phase of clinical research on inhaled insulin and have achieved gratifying results. Among them, Pfizer’s inhaled insulin --Exubera was approved in January 2006 listing. According to experts predict that the listing of inhaled insulin will cause no small impact on the insulin market. Whether this is the case or not, let’s wait and see.